Leerink Partners analyst Whit Mayo has maintained their bullish stance on BTSG stock, giving a Buy rating on May 5.
Whit Mayo has given his Buy rating due to a combination of factors that highlight BrightSpring Health Services, Inc.’s strong financial performance and strategic growth initiatives. The company’s first-quarter results for 2025 demonstrated robust momentum, driven by significant growth in specialty services and high demand from providers. The gross profit per prescription saw an impressive year-over-year increase, supported by the expansion of generic offerings and efficiency improvements.
Additionally, the provider segment showed strong performance, with notable revenue growth in the home health sector. The company’s strategic acquisition plans, including the potential purchase of agencies from AMED, are expected to enhance its market position. Furthermore, BrightSpring’s efforts to reduce leverage, alongside raised EBITDA forecasts and an increased price target, reinforce the positive outlook for the stock. These elements collectively contribute to Mayo’s optimistic assessment and Buy rating for BrightSpring Health Services, Inc.
According to TipRanks, Mayo is a 4-star analyst with an average return of 2.5% and a 48.72% success rate. Mayo covers the Healthcare sector, focusing on stocks such as Humana, Pediatrix Medical Group, and Encompass Health.
In another report released on May 5, BTIG also reiterated a Buy rating on the stock with a $25.00 price target.